Neogen Corporation Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net
Neogen Corporation (NEOG) reported Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net of $6.00 million for the 12-month period ending 2026-05-31, per its 10-K filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet · last filed 2026-07-30
- Neogen Corporation increase (decrease) in other noncurrent assets and liabilities, net for the quarter ending 2026-05-31 was $6.30M, a 125.00% increase year-over-year.
- Neogen Corporation increase (decrease) in other noncurrent assets and liabilities, net for the quarter ending 2026-02-28 was -$452.00K.
- Neogen Corporation increase (decrease) in other noncurrent assets and liabilities, net for the quarter ending 2025-11-30 was -$1.92M.
- Neogen Corporation increase (decrease) in other noncurrent assets and liabilities, net for the quarter ending 2025-08-31 was $2.07M, a 353.29% increase year-over-year.
- Neogen Corporation increase (decrease) in other noncurrent assets and liabilities, net for fiscal 2026 was $6.00M.
- Neogen Corporation increase (decrease) in other noncurrent assets and liabilities, net for fiscal 2025 was -$400.00K, a 101.85% decline from fiscal 2024.
- Neogen Corporation increase (decrease) in other noncurrent assets and liabilities, net for fiscal 2024 was $21.60M.
- Neogen Corporation increase (decrease) in other noncurrent assets and liabilities, net for fiscal 2023 was -$154.00K.
| Period end | Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net 6 month | Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net 9 month | Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net 9 month as first filed | Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net 12 month | Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-05-31 | $6.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-30 | $5.85M derived: sum of 2 quarters · filed 2026-07-30 | $3.93M derived: sum of 3 quarters · filed 2026-07-30 | $6.00M 10-K · filed 2026-07-30 | ||
| 2026-02-28 | -$452.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-04-09 | -$2.37M derived: sum of 2 quarters · filed 2026-04-09 | -$300.00K 10-Q · filed 2026-04-09 | $2.50M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-11-30 | -$1.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-01-08 | $152.00K 10-Q · filed 2026-01-08 | $2.95M derived: sum of 3 quarters · filed 2026-07-30 | $2.38M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-08-31 | $2.07M 10-Q · filed 2025-10-09 | $4.87M derived: sum of 2 quarters · filed 2026-07-30 | $4.30M derived: sum of 3 quarters · filed 2026-07-30 | $1.21M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-05-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-30 | $2.23M derived: sum of 2 quarters · filed 2026-07-30 | -$856.00K derived: sum of 3 quarters · filed 2026-07-30 | -$400.00K 10-K · filed 2026-07-30 | -$360.00K 10-K · filed 2025-07-30 | |
| 2025-02-28 | -$568.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-04-09 | -$3.66M derived: sum of 2 quarters · filed 2026-04-09 | -$3.20M 10-Q · filed 2026-04-09 | -$3.23M 10-Q · filed 2025-04-09 | $6.17M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2024-11-30 | -$3.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-01-08 | -$2.63M 10-Q · filed 2026-01-08 | $6.74M derived: sum of 3 quarters · filed 2026-07-30 | $9.08M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2024-08-31 | $456.00K 10-Q · filed 2025-10-09 | $9.82M derived: sum of 2 quarters · filed 2026-07-30 | $12.16M derived: sum of 3 quarters · filed 2026-07-30 | $16.05M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2024-05-31 | $9.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-30 | $11.71M derived: sum of 2 quarters · filed 2026-07-30 | $15.59M derived: sum of 3 quarters · filed 2026-07-30 | $21.60M 10-K · filed 2026-07-30 | $21.33M 10-K · filed 2024-07-30 | |
| 2024-02-29 | $2.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-04-09 | $6.23M derived: sum of 2 quarters · filed 2025-04-09 | $12.23M 10-Q · filed 2025-04-09 | $8.50M derived: sum of 4 quarters · filed 2025-07-30 | ||
| 2023-11-30 | $3.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-01-15 | $9.89M 10-Q · filed 2025-01-15 | $6.16M derived: sum of 3 quarters · filed 2025-07-30 | |||
| 2023-08-31 | $6.01M 10-Q · filed 2024-10-10 | $2.27M derived: sum of 2 quarters · filed 2025-07-30 | ||||
| 2023-05-31 | -$3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-30 | -$154.00K 10-K · filed 2025-07-30 | -$1.57M 10-K · filed 2023-08-15 | |||
| 2023-02-28 | $3.58M 10-Q · filed 2023-04-04 | |||||
| 2022-05-31 | $6.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | -$8.27M 10-K · filed 2024-07-30 | -$6.26M 10-K · filed 2023-08-15 | |||
| 2022-02-28 | -$14.46M 10-Q · filed 2023-04-04 | |||||
| 2021-05-31 | $879.00K 10-K · filed 2023-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |